Flecainide in patients with arrhythmic mitral valve syndrome: A case series
Eivind W. Aabel, Lars A. Dejgaard, Monica Chivulescu, Thomas Helle-Valle, Thor Edvardsen, Nina E. Hasselberg, Finn Hegbom, Øyvind Lie, Kristina H. Haugaa
Abstract
Arrhythmic symptoms are prevalent and life-threatening ventricular arrhythmias (VA) are a feared complication in patients with arrhythmic mitral valve syndrome (AMVS) (1). There is no established medical therapy to suppress VA and relieve arrhythmic symptoms in these patients beyond conventional beta-blocker therapy, which is often unsuccessful and not evaluated in randomized controlled trials. Catheter ablation can suppress VA in some patients, but is limited due to the multifocal nature of premature ventricular complexes (PVC), papillary muscle origin, and VA recurrence despite initial successful procedures.